Document is current
Any future updates will be listed below
-
Authors
Bain, Stephen C.
Belmar, Nicolas
Hoff, Søren T.
Husain, Mansoor
Rasmussen, Søren
Vilsbøll, Tina
Petrie, Mark C.
-
Funding
Funding for this research was provided by:
Novo Nordisk
- License Information
-
More Information
Article History
Received: 18 July 2024
Accepted: 30 September 2024
First Online: 9 November 2024
Declarations
:
: Stephen Bain has received honoraria, teaching and research sponsorship/grants from the following: AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, GSK, Merck Sharp & Dohme, Novo Nordisk, Pfizer, Sanofi, and Takeda. Stephen Bain is an Editorial Board member of Diabetes Therapy. Stephen Bain was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Nicolas Belmar, Søren Hoff, and Søren Rasmussen are employees of Novo Nordisk, and Søren Hoff and Søren Rasmussen are shareholders in Novo Nordisk. Mansoor Husain has received research grants from AstraZeneca, Merck, and Novo Nordisk, and advisory/consultancy fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, and Roche. Tina Vilsbøll has served on scientific advisory panels, been part of speakers’ bureaus, served as a consultant to and/or received research support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, GSK, Mundipharma, MSD/Merck, Novo Nordisk, Sanofi, and Sun Pharmaceuticals. Mark Petrie has received grants or contracts from AstraZeneca, Boehringer Ingelheim, Boston Scientific, Medtronic, Novartis, Novo Nordisk, Pharmacosmos, Roche, and SQ Innovation Inc; consulting fees and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis AG, Corvia Medical, Novartis, Novo Nordisk, Pharmacosmos, Siemens, Takeda, and Vifor; has participated in a Data Safety Monitoring Board or advisory board panels for AstraZeneca and Teikoku; and is a Director of Global Clinical Trials Partners.
: SUSTAIN 6 and PIONEER 6 were approved by independent ethics committees and institutional review boards at each participating center and conducted in compliance with the International Conference on Harmonization Good Clinical Practice guidelines and the Declaration of Helsinki. All participants provided written informed consent prior to any trial-related activities.
